Faruqi & Faruqi, LLP Urges Beta Bionics (BBNX) Investors to Seek Counsel Before November 3, 2026 Lead Plaintiff Deadline in the Securities Class Action

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX).

Faruqi & Faruqi, LLP, a leading national securities law firm, informs investors of the securities class action brought on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period").

To learn more about the Beta Bionics class action, go to www.faruqilaw.com/[BBNX](/en/us/BBNX) or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 3, 2026 . The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the Company's automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump ("iLet"). Throughout the Class Period, Defendants touted the safety, efficacy, and commercial success of the iLet, the Company's sole commercialized product.

After disclosing that the FDA had issued a Form 483 following an inspection of the Company's manufacturing facility, Defendants repeatedly assured investors that the agency's observations concerned only the Company's criteria for deciding which customer complaints were reportable, that they reflected no underlying problem with the device, and that the complaints the Company would now be required to report were minor events of the kind requiring no medical intervention.

In truth, the FDA's findings reached the Company's quality management system, its investigation and correction of known device malfunctions, and the risk analysis for the device itself, and the events the Company had failed to report included serious injuries. Defendants continued to reassure investors and to characterize the agency's concerns as procedural even as further information emerged showing that the unreported events were far more serious than Defendants had represented and that the FDA's objections were not confined to a difference in regulatory interpretation.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Beta Bionics' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Investors who purchased or acquired Beta Bionics (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) .